Title: Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.
Journal: Expert opinion on pharmacotherapy 20170801
Title: Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci.
Journal: International journal of antimicrobial agents 20110101
Title: The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009).
Journal: The Journal of infection 20101201
Title: Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis.
Journal: Antimicrobial agents and chemotherapy 20101201
Title: Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.
Journal: International journal of antimicrobial agents 20100601
Title: CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
Journal: Diagnostic microbiology and infectious disease 20100401
Title: In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
Journal: Antimicrobial agents and chemotherapy 20100101
Title: Clinical efficacy of ketolides in the treatment of respiratory tract infections.
Journal: The Journal of antimicrobial chemotherapy 20040601
Title: Replacement therapy in patients with hereditary antithrombin III deficiency.
Journal: Seminars in hematology 19910101
Title: Rodgers W, et al. Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus,Streptococcus pneumoniae, and Haemophilus influenzae. Antimicrob Agents Chemother. 2013 Apr;57(4):1632-1637.
Title: Kobayashi Y, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition. J Pharmacol Exp Ther. 2013 Apr;345(1):76-84.
